Clinical Trial Update: ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting [Phase 3]

View source ↗

Summary

Phase 3 trial update for ELUCIDATE investigating folate receptor targeting to enable lung cancer identification; study completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Lung Neoplasms

Drugs mentioned

• ELUCIDATE

Snippet

Sponsor: On Target Laboratories, LLC | Conditions: Lung Neoplasms, Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-03-23